|
|
|
|
|
Detail |
| hsa-miR-22 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNA expression profiling in prostate cancer. |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNAs: novel regulators involved in the pathogenesis of Psoriasis? |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. |
2008 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD |
2009 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation |
2009 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. |
2009 |
|
|
|
|
|
|
| hsa-miR-22 |
|
Unspecified |
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs |
2009 |
|
|
|
|
|
|